<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887935</url>
  </required_header>
  <id_info>
    <org_study_id>202107070</org_study_id>
    <nct_id>NCT04887935</nct_id>
  </id_info>
  <brief_title>Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer</brief_title>
  <official_title>Pilot Clinical Trial of Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the tolerability and safety of neoadjuvant dapagliflozin for patients with&#xD;
      high-risk or very high risk prostatic adenocarcinoma prior to radical prostatectomy. The&#xD;
      primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is&#xD;
      well-tolerated and safe to use in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of toxicities related to dapagliflozin as measured by CTCAE v 5.0</measure>
    <time_frame>From start of treatment through day 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients enrolled in 24 months</measure>
    <time_frame>Through 24 months</time_frame>
    <description>-Feasibility will be met if 24 patients are enrolled in 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in prostate tumor size as determined by pre-operative prostate MRI</measure>
    <time_frame>At the time of pre-operative prostate MRI (estimated to be at week 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of prostate tumor necrosis</measure>
    <time_frame>At the time of radical prostatectomy (estimated to be at week 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose</measure>
    <time_frame>From day 1 to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ketones</measure>
    <time_frame>From day 1 to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>From baseline to day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Cancer of Prostate</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy&#xD;
Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed localized prostatic adenocarcinoma. Patients&#xD;
             with primarily neuroendocrine/small cell histology will be excluded.&#xD;
&#xD;
          -  Patients with high risk or very high risk prostatic adenocarcinoma as defined by NCCN&#xD;
             criteria.&#xD;
&#xD;
               -  High risk is defined by NCCN as meeting at least one of the following criteria:&#xD;
&#xD;
                    -  T3a&#xD;
&#xD;
                    -  grade group 4 or 5&#xD;
&#xD;
                    -  PSA &gt; 20&#xD;
&#xD;
               -  Very high risk is defined by NCCN as meeting at least one of the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  T3b-T4&#xD;
&#xD;
                    -  primary Gleason pattern 5&#xD;
&#xD;
                    -  2-3 high risk features **&gt; 4 cores with grade group 4 or 5&#xD;
&#xD;
          -  Willing and able to undergo prostate MRI at baseline, with a measurable prostate&#xD;
             lesion present.&#xD;
&#xD;
          -  Planning to undergo radical prostatectomy as primary treatment for localized prostate&#xD;
             cancer.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Normal bone marrow and organ function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥ 3,000/mcL&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mcL&#xD;
&#xD;
               -  Platelets ≥ 100,000/mcL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN&#xD;
&#xD;
               -  Estimated glomerular filtration rate eGFR ≥ 30 mL/min/1.73m^2&#xD;
&#xD;
          -  Agreement to adhere to Lifestyle Considerations throughout study duration&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or previous treatment with SGLT2i or thiazolidinedione.&#xD;
&#xD;
          -  Currently receiving regularly scheduled systemic steroids in the form of prednisone or&#xD;
             dexamethasone. Topical steroid ointments or creams for occasional skin rash is&#xD;
             allowed.&#xD;
&#xD;
          -  A history of other malignancy with the exceptions of malignancies for which all&#xD;
             treatment was completed at least 2 years before registration with no evidence of&#xD;
             disease and locally treated skin squamous or basal cell carcinoma.&#xD;
&#xD;
          -  History of stroke or transient ischemic attack in the last 5 years.&#xD;
&#xD;
          -  Patients with type 1 diabetes mellitus will be excluded.&#xD;
&#xD;
          -  HbA1c &gt; 10%, unless approved by endocrinologist. No patients with insulin-requiring&#xD;
             diabetes mellitus will be allowed.&#xD;
&#xD;
          -  Currently receiving any other investigational agents.&#xD;
&#xD;
          -  A history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to dapagliflozin.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, peripheral arterial disease, ketoacidosis, severe kidney disease&#xD;
             (estimated glomerular filtration rate eGFR &lt; 30 mL/min/1.73m2), symptomatic&#xD;
             hypotension, and chronic/frequent urinary tract infections or yeast infections.&#xD;
&#xD;
          -  Patients with HIV are eligible unless their CD4+ T-cell counts are &lt; 350 cells/mcL or&#xD;
             they have a history of AIDS-defining opportunistic infection within the 12 months&#xD;
             prior to registration. Concurrent treatment with effective ART according to DHHS&#xD;
             treatment guidelines is recommended.&#xD;
&#xD;
          -  Any evidence of pelvic instrumentation (i.e. hip arthroplasty) that would obscure&#xD;
             and/or limit prostate MRI evaluation at the discretion of the investigator, or any&#xD;
             type of medical device that would be incompatible with MRI imaging.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa A Reimers, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa A Reimers, M.D.</last_name>
    <phone>314-362-5740</phone>
    <email>mreimers@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melissa A Reimers, M.D.</last_name>
      <phone>314-362-5740</phone>
      <email>mreimers@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa A Reimers, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda R Peterson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph E Ippolito, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Andriole, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet McGill, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingqin (Rosy) Luo, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

